[Use of a new steroid (Org OD 14) in the climacteric syndrome].
A double-blind study was carried out in 60 women with climacteric symptoms: 30 women were given Org OD 14 (2.5 mg) and 30 were given a placebo to be taken daily for six weeks. The effects of the medication on the climacteric symptoms, the subjective sensations, the plasma FSH levels and endometrial histology were studied. In the treated group compared with the control group the relief or improvement of the following climacteric symptoms were recorded: perspiration, palpitations, irritability and backache. A favourable effect on the subjective sensations was noted in both groups, although no significant difference for the group which received Org OD 14 was found. At the end of the treatment with Org OD 14, the FSH levels were found to be greatly reduced in comparison with the basal values; this, however, was not the case with the placebo group. With regard to endometrial histology, no sign of hyperplasia was found in any of the patients. No relevant side effects or symptoms of estrogenic or androgenic stimulation were recorded. For the climacteric patient needing estrogen therapy, it can be concluded that Org OD 14 is an effective and innocuous medication in the doses used.
D000328:Adult; D002979:Climacteric / Q000187:drug effects*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004644:Emotions / Q000187:drug effects; D004717:Endometrium / Q000187:drug effects; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D008875:Middle Aged; D009652:Norpregnenes / Q000494:pharmacology / Q000627:therapeutic use*; D011897:Random Allocation; D013577:Syndrome
D009652:Norpregnenes; D005640:Follicle Stimulating Hormone; C027385:tibolone
Uso de un nuevo esteroide (Org OD 14) en el síndrome climatérico.